Pulmonary Embolism Clinical Trial
Official title:
Examination of the Standardized Use of the Pulmonary Embolism SOP in the Clinical Routine of the Emergency Department in Respect of the QEST Criteria (Quality, Efficacy, Safety and Transparency).
Usage of a guideline-compliant SOP in each chest pain unit (CPU) is instrumental in establishing the diagnosis of a pulmonary embolism without time delay. With the integration of this SOP as a "clinical decision tool" (CDT) into the electronic database of the CPU, the standardized application of the pulmonary embolism SOP in the clinical routine of the CPU will be tested using a retro- and prospective approach.
Summary:
The increasing number of patients in the emergency departments in recent years extends the
time until diagnosis and treatment initiation and thus represents a serious problem in
patient care and for the treating physician. This also includes patients with acute pulmonary
embolism (PE), which is one of the most common differential diagnoses of patients presenting
with unclear dyspnea, chest pain or other symptoms in the emergency department. Due to the
potentially serious clinical outcome with a high overall mortality rate of > 10%, rapid
diagnosis and initiation of therapy is essential.
The current guidelines of the European Society of Cardiology for the diagnosis and treatment
of acute PE recommend a stringent diagnostic algorithm that includes clinical parameters as
well as risk scores for estimating the pretest probability. Depending of their results the
further diagnostic pathway by D-Dimer testing and / or CT angiography is chosen.
The aim of the present study is to examine the standardized application of guideline
recommendations of the European Society of Cardiology (ESC). The diagnostic procedures were
defined for the CPU of the University Hospital Heidelberg in a standard operating procedure
(SOP). In the planned retrospective study, the implementation of this SOP will be examined on
the basis of the QEST criteria (quality, efficacy, safety and transparency). Data for the
"actual condition" are collected retrospectively for 6 months prior to August 2019,
thereafter for another 6 months after implementation of the quality assurance measure.
Introduction and fundamental principles:
Acute pulmonary embolism (PE), with a prevalence of 1.22-1.83 persons per 100,000 population,
is the third most common cardiovascular disease and represents a serious disease with a
30-day mortality from potential right ventricular dysfunction with cardiogenic shock
estimated at 16%. Approximately 65% of all deaths occur within the first hours after
admission. The prognosis of pulmonary embolism is highly variable and depends in particular
on the severity of the hemodynamic impairment as well as on concomitant morbidities.
Due to multiple and sometimes non-specific symptoms, the diagnosis of PE poses a clinical
challenge and requires much clinical experience in order not to overlook the diagnosis.
Clinical scores (Well's Score, Geneva Score, modified Geneva Score) and the overall clinical
impression (gestalt) are used to estimate the pretest probability. The current guidelines of
the European Society of Cardiology on the diagnosis and management of acute pulmonary
embolism recommend a stringent diagnostic algorithm which includes clinical parameters and
the above-mentioned risk scores for the assessment of the pretest probability and on the
basis of them further diagnostic steps by D-dimer measurement and / or CT angiography. With a
low pretest probability, a pulmonary embolism can be excluded with a probability of nearly
100%. On the other hand, if there is a high pretest probability, no D-dimer determination
should be made, as even a negative result will not be able to exclude the diagnosis with
certainty. The procedure for a mean pretest probability depends on the D-dimer test used.
Determination of D-dimers should only be undertaken if an analytically sensitive D-dimer test
is present, which is ideally authorized for the purpose of diagnostic exclusion. The central
laboratory of the University Hospital of Heidelberg uses the Siemens Liason D-Dimer test,
which is considered one of the most sensitive tests. From the diagnostic procedure, a
sequential pathway is recommended in which first the pre-test probability and then -
depending on the estimate - the D-dimer determination follows. If pulmonary embolism cannot
be ruled out, further diagnostic imaging should be provided. CT angiography with a
multi-slice device (> 16-slices) is considered the diagnostic gold standard.
However, the guideline-compliant algorithm for the diagnosis of PE has so far only been
investigated in a few prospective, randomized studies.
The aim of the present study is to test the standardized use of the pulmonary embolism SOP in
the clinical routine of the CPU compared to the "actual state". Currently, the attending
physician has unrestricted access to the determination of the D-dimer concentration, and the
diagnostic process continues to be carried out at clinical discretion. These two approaches
are to be tested and compared with regard to the QEST criteria (quality, efficacy, safety and
transparency).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |